Skip to main content
Premium Trial:

Request an Annual Quote

The BioCommerce Week Index: May 5, 2005

BioCommerce Week's Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(May 3 , 2005)
Last Price
(
April 26, 2005)
% Change
Agilent
A
21.18
21.34
-0.75
Applied Biosystems
ABI
22.62
20.19
12.04
BD
BDX
59.17
56.55
4.63
Beckman
BEC
67.04
66.34
1.06
Bio-Rad
BIO
49.62
49.21
0.83
Bruker
BRKR
3.4
3.16
7.59
GE
GE
36.1
36.18
-0.22
Harvard Bio
HBIO
3.82
3.8
0.53
Invitrogen
IVGN
75.2
73.51
2.30
Molecular Devices
MDCC
18.42
18.6
-0.97
PerkinElmer
PKI
18.01
19.87
-9.36
Sigma
SIAL
59.44
57.6
3.19
Stratagene
STGN
8.2
8.11
1.11
Thermo
TMO
25.41
25.21
0.79
Waters
WAT
39.83
39
2.13
Index Average  
33.83
33.24
1.78

ABI Leads BCW Index with 12 Percent Gain for the Week

Shares in Applied Biosystems gained 12 percent to $22.62 during the five-day period ending Tuesday, leading the basket of multiplatform molecular biology tools companies whose shares are tracked in the BioCommerce Week Index. The strong performance comes in the week following the release of the firm's third-quarter financial results, which showed a foreign-exchange-aided 3-percent increase in revenues of $455 million.

Although the big news of the week was Beckman Coulter's announcement to purchase privately held DNA sequencing services firm Agencourt Bioscience (see related story), shares in the company nudged up only 1 percent during the tracking period. PerkinElmer experienced the biggest decline of the week, dropping 9.36 percent to $18.01, despite reporting 6-percent revenue growth and beating analysts' consensus per-share estimate by a penny for the first quarter of 2005.

Overall, the BCW index gained 1.78 percent to $33.83 on Tuesday, closing up for the second consecutive week. The index outgained the Dow Jones Industrial Average, which rose 1 percent, as well as the Nasdaq, which gained .3 percent, and the S&P 500, which closed the 5-day period up .82 percent. The Amex Pharma Index gained 2.7 percent.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.